الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - triazolam - tabletter - 0,125 mg

الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - triazolam - tabletter - 0,25 mg

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

teva b.v. - fentanyl - pain; cancer - analgetika - effentora er indiceret til behandling af gennembrudssmerter (btp) hos voksne med cancer, som allerede modtager vedligeholdelsesopioidbehandling til kronisk kræftpine. btp er en forbigående forværring af smerter, der opstår på baggrund af en ellers kontrolleret vedvarende smerter. patienter, der modtager vedligeholdelse opioidbehandling er dem, der tager mindst 60 mg oral morfin dagligt, mindst 25 mikrogram af transdermal fentanyl per time, mindst 30 mg oxycodon dagligt, mindst 8 mg oral hydromorphone dagligt eller en equianalgesic dosis af et andet opioid for en uge eller længere.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

takeda pharma a/s - fentanyl citrate - pain; cancer - analgetika - instanyl er indiceret til behandling af gennembrudssmerter hos voksne, der allerede modtager opioidbehandling ved vedligeholdelse af kronisk kræftpine. gennembrudssmerter er en forbigående forværring af smerte, der opstår på baggrund af ellers kontrolleret vedvarende smerte.  patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacinhydrochlorid - attention deficit disorder med hyperaktivitet - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv skal bruges som en del af et omfattende adhd behandling program, typisk, herunder psykologiske, pædagogiske og sociale foranstaltninger.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

incline therapeutics europe ltd - fentanylhydrochlorid - smerte, postoperative - analgetika - ionsys er indiceret til behandling af akut moderat til svær postoperativ smerte hos voksne patienter.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - polycystic kidney, autosomal dominant - diuretika, - jinarc er indiceret til at bremse udviklingen af cyste udvikling og nyreinsufficiens af autosomal dominerende polycystisk nyresygdom (adpkd) hos voksne med cementovnstøv fase 1 til 3 på indledning af behandling med beviser for hastigt fremad sygdom.